Does the media favor LBRX or INDV?

In the previous week, LB Pharmaceuticals had 11 more articles in the media than Indivior. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 3 mentions for Indivior. Indivior's average media sentiment score of 1.31 beat LB Pharmaceuticals' score of 0.63 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LBRX or OGN?

In the previous week, LB Pharmaceuticals had 10 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.82 beat LB Pharmaceuticals' score of 0.63 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LBRX or RGC?

LB Pharmaceuticals presently has a consensus price target of $57.40, indicating a potential upside of 64.99%. Given LB Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe LB Pharmaceuticals is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LB Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, LBRX or RGC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LB Pharmaceuticals N/A N/A -$25.20M -$3.44 N/A Regencell Bioscience N/A N/A -$11.70M N/A N/A

Is LBRX or RGC more profitable?

Regencell Bioscience's return on equity of 0.00% beat LB Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A -25.92% -24.68% Regencell Bioscience N/A N/A N/A

Does the media refer more to LBRX or RGC?

In the previous week, LB Pharmaceuticals had 10 more articles in the media than Regencell Bioscience. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 4 mentions for Regencell Bioscience. LB Pharmaceuticals' average media sentiment score of 0.63 beat Regencell Bioscience's score of 0.62 indicating that LB Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TARS or LBRX?

In the previous week, LB Pharmaceuticals had 9 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 5 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.65 beat LB Pharmaceuticals' score of 0.63 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 2 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARQT or LBRX?

In the previous week, LB Pharmaceuticals had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 11 mentions for Arcutis Biotherapeutics. LB Pharmaceuticals' average media sentiment score of 0.63 beat Arcutis Biotherapeutics' score of 0.62 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 2 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

LB Pharmaceuticals (LBRX) Competitors

$34.79 -1.14 (-3.17%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$40.15 +5.36 (+15.41%)

As of 07:19 AM Eastern

Compare

LBRX vs. INDV, OGN, RGC, TARS, and ARQT

Should you buy LB Pharmaceuticals stock or one of its competitors? LB Pharmaceuticals's main competitors and comparable companies include Indivior (INDV), Organon & Co. (OGN), Regencell Bioscience (RGC), Tarsus Pharmaceuticals (TARS), and Arcutis Biotherapeutics (ARQT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LB Pharmaceuticals compare to Indivior?

LB Pharmaceuticals (NASDAQ:LBRX) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Indivior has a net margin of 26.65% compared to LB Pharmaceuticals' net margin of 0.00%. LB Pharmaceuticals' return on equity of -25.92% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Indivior	26.65%	-283.11%	36.85%

LB Pharmaceuticals currently has a consensus price target of $57.40, suggesting a potential upside of 64.99%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 27.52%. Given LB Pharmaceuticals' higher possible upside, analysts plainly believe LB Pharmaceuticals is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

60.3% of Indivior shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, LB Pharmaceuticals had 11 more articles in the media than Indivior. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 3 mentions for Indivior. Indivior's average media sentiment score of 1.31 beat LB Pharmaceuticals' score of 0.63 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Indivior	$1.24B	3.37	$210M	$2.79	12.70

Summary

Indivior beats LB Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Organon & Co.?

LB Pharmaceuticals (NASDAQ:LBRX) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Organon & Co. has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.89

Organon & Co. has a net margin of 3.41% compared to LB Pharmaceuticals' net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Organon & Co.	3.41%	88.97%	6.03%

77.4% of Organon & Co. shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, LB Pharmaceuticals had 10 more articles in the media than Organon & Co.. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.82 beat LB Pharmaceuticals' score of 0.63 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LB Pharmaceuticals presently has a consensus price target of $57.40, suggesting a potential upside of 64.99%. Organon & Co. has a consensus price target of $11.40, suggesting a potential downside of 17.24%. Given LB Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe LB Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Summary

Organon & Co. beats LB Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Regencell Bioscience?

LB Pharmaceuticals (NASDAQ:LBRX) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A
Regencell Bioscience	N/A	N/A	-$11.70M	N/A	N/A

0.1% of Regencell Bioscience shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Regencell Bioscience's return on equity of 0.00% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	-25.92%	-24.68%
Regencell Bioscience	N/A	N/A	N/A

LB Pharmaceuticals presently has a consensus price target of $57.40, indicating a potential upside of 64.99%. Given LB Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe LB Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, LB Pharmaceuticals had 10 more articles in the media than Regencell Bioscience. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 4 mentions for Regencell Bioscience. LB Pharmaceuticals' average media sentiment score of 0.63 beat Regencell Bioscience's score of 0.62 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LB Pharmaceuticals beats Regencell Bioscience on 6 of the 10 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and LB Pharmaceuticals (NASDAQ:LBRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals currently has a consensus price target of $100.86, indicating a potential upside of 42.41%. LB Pharmaceuticals has a consensus price target of $57.40, indicating a potential upside of 64.99%. Given LB Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe LB Pharmaceuticals is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

LB Pharmaceuticals has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Tarsus Pharmaceuticals' return on equity of -13.53% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

In the previous week, LB Pharmaceuticals had 9 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 5 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.65 beat LB Pharmaceuticals' score of 0.63 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	2 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LB Pharmaceuticals has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.88	-$66.42M	-$1.09	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

Summary

Tarsus Pharmaceuticals beats LB Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and LB Pharmaceuticals (NASDAQ:LBRX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Arcutis Biotherapeutics has a net margin of 6.15% compared to LB Pharmaceuticals' net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

Arcutis Biotherapeutics has higher revenue and earnings than LB Pharmaceuticals. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.72	-$16.14M	$0.21	124.24
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

Arcutis Biotherapeutics currently has a consensus price target of $36.00, indicating a potential upside of 37.98%. LB Pharmaceuticals has a consensus price target of $57.40, indicating a potential upside of 64.99%. Given LB Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe LB Pharmaceuticals is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, LB Pharmaceuticals had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 14 mentions for LB Pharmaceuticals and 11 mentions for Arcutis Biotherapeutics. LB Pharmaceuticals' average media sentiment score of 0.63 beat Arcutis Biotherapeutics' score of 0.62 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	2 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcutis Biotherapeutics beats LB Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get LB Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LBRX vs. The Competition

Export

Metric	LB Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.16B	$12.37B	$7.27B	$13.21B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	-10.11	646.11	202.90	19.69
Price / Sales	N/A	749.61	561.48	81.34
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	2.92	9.21	10.61	6.03
Net Income	-$25.20M	$2.83B	$3.50B	$380.34M
7 Day Performance	1.84%	-3.41%	-2.89%	-2.34%
1 Month Performance	-22.41%	-7.47%	-7.37%	-5.31%
1 Year Performance	122.73%	-5.62%	3.00%	-2.94%

LB Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LBRX LB Pharmaceuticals	2.465 of 5 stars	$34.79 -3.2%	$57.40 +65.0%	+116.5%	$1.16B	N/A	N/A	27	Analyst Downgrade
INDV Indivior	4.5096 of 5 stars	$35.99 +0.8%	$45.17 +25.5%	+48.4%	$4.21B	$1.24B	12.90	838	Positive News
OGN Organon & Co.	1.3612 of 5 stars	$13.72 0.0%	$11.40 -16.9%	+43.4%	$3.60B	$6.22B	17.81	10,000
RGC Regencell Bioscience	0.2607 of 5 stars	$7.24 +6.2%	N/A	-54.5%	$3.37B	N/A	N/A	10	Earnings Report High Trading Volume
TARS Tarsus Pharmaceuticals	3.3831 of 5 stars	$74.46 +2.0%	$100.86 +35.5%	+0.7%	$3.20B	$451.36M	N/A	370

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LBRX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. INDV, OGN, RGC, TARS, and ARQT

How does LB Pharmaceuticals compare to Indivior?

Summary

How does LB Pharmaceuticals compare to Organon & Co.?

Summary

How does LB Pharmaceuticals compare to Regencell Bioscience?

Summary

How does LB Pharmaceuticals compare to Tarsus Pharmaceuticals?

Summary

How does LB Pharmaceuticals compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. INDV, OGN, RGC, TARS, and ARQT

How does LB Pharmaceuticals compare to Indivior?

Is LBRX or INDV more profitable?

Do analysts prefer LBRX or INDV?

Do insiders and institutionals hold more shares of LBRX or INDV?

Does the media favor LBRX or INDV?

Which has higher valuation and earnings, LBRX or INDV?

Summary

How does LB Pharmaceuticals compare to Organon & Co.?

Which has stronger valuation and earnings, LBRX or OGN?

Is LBRX or OGN more profitable?

Do institutionals and insiders have more ownership in LBRX or OGN?

Does the media prefer LBRX or OGN?

Do analysts rate LBRX or OGN?

Summary

How does LB Pharmaceuticals compare to Regencell Bioscience?

Which has stronger valuation and earnings, LBRX or RGC?

Do institutionals & insiders have more ownership in LBRX or RGC?

Is LBRX or RGC more profitable?

Do analysts rate LBRX or RGC?

Does the media refer more to LBRX or RGC?

Summary

How does LB Pharmaceuticals compare to Tarsus Pharmaceuticals?

Do insiders and institutionals have more ownership in TARS or LBRX?

Do analysts prefer TARS or LBRX?

Is TARS or LBRX more profitable?

Does the media favor TARS or LBRX?

Which has preferable earnings & valuation, TARS or LBRX?

Summary

How does LB Pharmaceuticals compare to Arcutis Biotherapeutics?

Is ARQT or LBRX more profitable?

Which has stronger earnings & valuation, ARQT or LBRX?

Do analysts recommend ARQT or LBRX?

Does the media favor ARQT or LBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools